GLP-1 seller Hims & Hers Health (NYSE: HIMS) has seen significant volatility in its stock price as of late. Notably, despite seeing a 41% single-day surge in early March, HIMS remains down nearly 10% ...
・HIMS to offer treatment options for perimenopause and menopause via its platform ・Rising U.S. demand for hormone therapy strains supplies of estrogen patches. ・BofA raises HIMS price target but ...
Hims & Hers Health shares have surged 45% in 30 days on GLP-1 coverage shifts, but overbought technicals, a Hold rating, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results